Treatment response rate and life prognosis at autoimmune liver diseases
Abstract
The aim of review. To carry out comparative analysis of modern studies, to characterize actual modes of treatment and to define prognosis and features of treatment response at various autoimmune liver diseases.
Key points. Diagnostics and treatment are the most complex and insufficiently investigated aspects of autoimmune liver diseases. Due to large studies, clinicians gain some understanding of approaches to therapy of these patients. Article presents up-to-date management algorithms and new promising agents, demonstrates complexities and alternative variants of treatment of autoimmune liver diseases.
Conclusion. Appropriate and long-term (for 12–24 months) therapy of autoimmune diseases in most cases allows to achieve sustained response and in several folds surpasses efficacy of short courses (6–12 months).
About the Authors
K. V. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Ivashkin Konstantin V. — MD, assistant-professor, chair of internal diseases propedeutics
119991, Moscow, Pogodinskaya street, 1, bld 1
Ye. N. Shirokova
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Ivashkin V.T. Liver and biliary diseases M.: Publishing house «M-Vesti», 2005.536 p.
2. Ivashkin V.T., Buyeverov A.O. Autoimmune liver diseases in clinical practice M.: Publishing house «M-Vesti», 2011. 112 p.
3. Manns M.P., Czaja A.J., Gorham J.D. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193-213.
4. Czaja A.J. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51:161-7.
5. Murray-Lyon I.M., Stern R.B., Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1:735-7.
6. Kanzler S., Lohr H., Gerken G., Galle P.R., Lohse A.W. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001; 39:339-41, 344-8.
7. Seo S., Toutounjian R., Conrad A., Blatt L., Tong M.J. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008; 23:1410-4.
8. Czaja A.J., Carpenter H.A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40:646-52.
9. Kanzler S., Gerken G., Lohr H. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34:354-5.
10. Czaja A.J., Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36:479-96.
11. Malekzadeh R., Nasseri-Moghaddam S., Kaviani M.J., Taheri H., Kamalian N., Sotoudeh M. Cyclosporine A in a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46:1321-7.
12. Aqel B.A., Machicao V., Rosser B., Satyanarayana R., Harnois D.M., Dickson R.C. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38:805-9.
13. Aw M.M., Dhawan A., Samyn M., Bargiota A., MieliVergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51:156-60.
14. Zandieh I., Krygier D., Wong V., Howard J., Worobetz L., Minuk G., Witt-Sullivan H., Yoshida E.M. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008; 22:388-92.
15. Kessler W.R., Cummings O.W., Eckert G., Chalasani N., Lumeng L., Kwo P.Y. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2:625-31.
16. Ichai P., Duclos-Vallee J.C., Guettier C., Hamida S.B., Antonini T., Delvart V., Saliba F., Azoulay D., Castaing D., Samuel D. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13:996-1003.
17. Czaja A.J. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007; 13:953-5.
18. Montano-Losa A.J., Carpenter H.A., Czaja A.J. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46:1138-45.
19. Czaja A.J., Carpenter H.A. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003; 23:116-23.
20. Stellon A.J., Keating J.J., Johnson P.J., McFarlane I.G., Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988; 8:781-4.
21. Johnson P.J., McFarlane I.G., Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333:958-63.
22. Buchel E., Van Steenbergen W., Nevens F., Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002; 97:3160-5.
23. Schramm C., Herkel J., Beuers U., Kanzler S., Galle P.R., Lohse A.W. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101:556-60.
24. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid «mechanisms of action and clinical use in hepatobiliary disorders». J Hepatol 2001; 35:134-46.
25. Lindor K.D., Kowdley K.V., Luketic V.A., Harrison M.E., McCashland T., Befeler A.S., Harnois D., Jorgensen R., Petz J., Keach J., Mooney J., Sargeant C., Braaten J., Bernard T., King D., Miceli E., Schmoll J., Hoskin T., Thapa P., Enders F. Highdose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50:808-14.
26. Pares A., Rodes J. Treatment of primary biliary cirrhosis. Minerva Gastroenterol Dietol 2000; 46:165-74.
27. Ivashkin V.T., Shirokova Ye.N. Cholestasis: Manual for doctors М., 2012.
28. Poupon R.E., Lindor K.D., Cauch-Dudek K., Dickson E.R., Poupon R., Heathcote E.J. Combined analysis or random controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-90.
29. Angulo P., Lindor K.D. Primary sclerosing cholangitis. Hepatology 1999; 30:325-32.
30. Pares A., Caballeria L., Rodes. J., Bruguera M., Rodrigo L., Garcia-Plaza A., Berenquer J., RodriquezMartinez D., Mercader J., Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from Spanish Association for the Study of the Liver. J Hepatol 2000; 32:561-6.
31. Gong Y., Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev 2004; 2: CD004481.
32. Hendrickse M.T., Rigney E., Giaffer M.H., Soomro I., Triger D.R., Underwood J.C., Gleeson D. Lowdose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999; 117:400-7.
33. Dickson E.R., Grambsch P.M., Fleming T.R., Fisher L.D., Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
34. Lombard M., Portmann B., Neuberger J., Williams R., Tyqstrup N., Ranek L., Ring-Larsen H., Rodes J., Navasa M., Trepo C. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993; 104:519-26.
35. Mitchison H.C., Palmer J.M., Bassendine M.F., Watson A.J., Record C.O., James O.F. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992; 15:336-44.
36. Christensen E., Neuberger J., Crowe J., Altman D.G., Popper H., Portmann B., Doniach D., Ranek L., Tyqstrup N., Williams R. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985; 89:1084-91.
37. Talwalkar J.A., Angulo P., Keach J.C., Petz J.L., Jorgensen R.A., Lindor K.D. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005; 39:168-71.
38. Angulo P., Lindor K.D. Medical treatment for primary sclerosing cholangitis: Risk versus benefit. Hepatology 2000; 32:871-2.
39. Levy C., Peter J.A., Nelson D.R., Keach J., Petz J., Cabrera R., Clark V., Firpi R.J., Morelli G., SoldevilaPico C., Lindor K. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011; 33:235-42.
40. Roglans N., Vazquez-Carrera M., Alegret M., Novell F., Zambon D., Ros E., Laguna J.C., Sanchez R.M. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol 2004; 59:855-61.
41. Matsumoto T., Miyazaki H., Nakahashi Y., Hirohara J., Seki T., Inoue K., Okazaki K. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004; 30:125-36.
42. Lindor K.D. New treatment strategies for primary sclerosing cholangitis. Dig Dis 2011; 29:113-6.
43. Fickert P., Wagner M., Marschall H.U., Fuchsbichler A., Zollner G., Tsybrovskyy O., Zatloukal K., Liu J., Waalkes M.P., Cover C., Hofmann A.F., Jaeschke H., Trauner M. 24-norUrsdeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130:465-81.
44. MacQuillan G.C., Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003; 7:941-56.
45. Sylvestre P.B., Batts K.P., Burgart L.J., Poterucha J.J., Wiesner R.H. Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history. Liver Transpl 2003; 9:1086-93.
46. Beuers U., Boberg K.M., Chapman R.W. EASL Clinical Practice Guidelines: Management of cholestatic liver disease. J Hepatol 2009; 51:237-67.
47. Olsson R., Glaumann H., Almer S. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009; 20:190-6.
48. Lindor K.D. Farnesoid X receptor agonist for primary biliary cirrhosis. Curr Opin Gastroenterol 2011; 27:285-8.
49. Fickert P., Zollner G., Fuschsbichler A., Stumptner C., Weiglein A.H., Lammert F., Marschall H.U., Tsybrovskyy O., Zatloukal K., Denk H., Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123:1238-51.
50. Floreani A., Rizzotto E.R., Ferrara F., Carderi I., Caroli D., Blasone L., Baldo V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100:1516-22.
51. Talwalkar J.A., Keach J.C., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002; 97:1191-7.
52. Twaddell W.S., Lefkowitch J., Berk P.D. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/ autoimmune hepatitis overlap syndrome. Semin Liver Dis 2008; 28:128-34.
53. Ben-Ari Z., Czaja A.J. Autoimmune hepatitis and its variant syndromes. Gut 2001; 49:589-94.
54. Czaja A.J. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci 2011; 56:3421-38.
55. Bittencourt P.L., Farias A.Q., Porta G., Cancado E.L., Miura I., Pugliese R., Kalil J., Goldberg A.C., Carrilho F.J. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008; 42:300-5.
56. Gregorio G.V., Portmann B., Karani J., Harrison P., Donaldson P.T., Vergani D., Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33:544-53.
57. Abdalian R., Dhar P., Jhaveri K., Haider M., Guindi M., Heathcote E.J. Prevalence of sclerosing cholangitis in adult with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47:949-57.
58. Angulo P., Maor-Kendler Y., Lindor K.D. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35:1494-500.
59. Kim W.R., Ludwig J., Lindor K.D. Variants forms of cholestatic disease involving small bile ducts in adults. Am J Gastroenterol 2000; 95:1130-8.
60. Perdigoto R., Carpenter H.A., Czaja A.J. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14:325-31.
61. Kenny R.P., Czaja A.J., Ludwig J., Dickson E.R. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986; 31:705-11.
62. Lewin M., Vilgrain V., Ozenne V., Lemoine M., Wendum D., Paradis V., Ziol M., Arrive L., Beaugrand M., Poupon R., Valla D., Chazouilleres O., Corpechot C. Prevalence of sclerosing cholangitis in adult with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009; 50:528-37.
63. Al-Chalabi T., Underhill J.A., Portmann B.C., McFarlane I.G., Heneghan M.A. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 2008; 6:1389-95.
64. Heathcote J. Variant syndromes of autoimmune hepatitis. Clin. Liver Dis. 2002; 6:669-84.
65. Boberg K.M., Fausa O., Haaland T., Holter E., Mellbye O.J., Spurkland A., Schrumf E. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23:1369-76.
66. Farias A.Q., Goncalves L.L., Bittencourt P.L., De Melo E.S., Abrantes-Lemos C.P., Porta G., Nakhle M.C., Carrilho F.J., Cancado E.L. Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/ anti-M2 seropositive variant form of autoimmune hepatitis. J Gastroenterol Hepatol 2006; 21:887-93.
67. Ivashkin K.V. Comparative analysis of clinical course, clinical and immunologic features, treatment response rates and life prognosis of patients with autoimmune hepatitis and overlap syndromes AIH/PBC, AIH/PSC: Author's abstract MD degree thesis. М., 2013; 24 p.
68. Ivashkin V.T., Sheptulina A.F., Raykhelson K.L., Losik E.A., Ivashkin K.V., Okhlobystin A.V., Baranskaya Ye.K., Poluektova Ye.A., Shifrin O.S. Autoimmune diseases of digestive system. The bulletin of Russian Academy of Medical Science 2015; 70(2):139-51. Doi:10.15690/vramn.v70i2.1306
Review
For citations:
Ivashkin K.V., Shirokova Ye.N., Ivashkin V.T. Treatment response rate and life prognosis at autoimmune liver diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(5):46-56. (In Russ.)
Views:
159
Email this article 
